Kiniksa Pharmaceuticals International (KNSA) Competitors $37.89 -0.22 (-0.58%) Closing price 10/10/2025 04:00 PM EasternExtended Trading$38.10 +0.21 (+0.56%) As of 10/10/2025 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock KNSA vs. ROIV, QGEN, ELAN, BBIO, MRNA, VRNA, RVMD, GRFS, RYTM, and RNAShould you be buying Kiniksa Pharmaceuticals International stock or one of its competitors? The main competitors of Kiniksa Pharmaceuticals International include Roivant Sciences (ROIV), QIAGEN (QGEN), Elanco Animal Health (ELAN), BridgeBio Pharma (BBIO), Moderna (MRNA), Verona Pharma PLC American Depositary Share (VRNA), Revolution Medicines (RVMD), Grifols (GRFS), Rhythm Pharmaceuticals (RYTM), and Avidity Biosciences (RNA). These companies are all part of the "pharmaceutical products" industry. Kiniksa Pharmaceuticals International vs. Its Competitors Roivant Sciences QIAGEN Elanco Animal Health BridgeBio Pharma Moderna Verona Pharma PLC American Depositary Share Revolution Medicines Grifols Rhythm Pharmaceuticals Avidity Biosciences Kiniksa Pharmaceuticals International (NASDAQ:KNSA) and Roivant Sciences (NASDAQ:ROIV) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, dividends, valuation, earnings, analyst recommendations, media sentiment, risk and institutional ownership. Which has higher valuation & earnings, KNSA or ROIV? Kiniksa Pharmaceuticals International has higher revenue and earnings than Roivant Sciences. Roivant Sciences is trading at a lower price-to-earnings ratio than Kiniksa Pharmaceuticals International, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKiniksa Pharmaceuticals International$423.24M6.63-$43.19M$0.04947.25Roivant Sciences$29.05M377.05-$171.98M-$0.70-22.91 Is KNSA or ROIV more profitable? Kiniksa Pharmaceuticals International has a net margin of 0.90% compared to Roivant Sciences' net margin of -2,111.79%. Kiniksa Pharmaceuticals International's return on equity of 1.05% beat Roivant Sciences' return on equity.Company Net Margins Return on Equity Return on Assets Kiniksa Pharmaceuticals International0.90% 1.05% 0.80% Roivant Sciences -2,111.79%-15.90%-14.95% Do analysts recommend KNSA or ROIV? Kiniksa Pharmaceuticals International presently has a consensus price target of $44.29, indicating a potential upside of 16.88%. Roivant Sciences has a consensus price target of $19.94, indicating a potential upside of 24.30%. Given Roivant Sciences' stronger consensus rating and higher probable upside, analysts plainly believe Roivant Sciences is more favorable than Kiniksa Pharmaceuticals International.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kiniksa Pharmaceuticals International 0 Sell rating(s) 2 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.78Roivant Sciences 1 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 2.80 Do insiders and institutionals believe in KNSA or ROIV? 54.0% of Kiniksa Pharmaceuticals International shares are owned by institutional investors. Comparatively, 64.8% of Roivant Sciences shares are owned by institutional investors. 53.5% of Kiniksa Pharmaceuticals International shares are owned by insiders. Comparatively, 10.8% of Roivant Sciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Which has more volatility and risk, KNSA or ROIV? Kiniksa Pharmaceuticals International has a beta of 0.16, meaning that its stock price is 84% less volatile than the S&P 500. Comparatively, Roivant Sciences has a beta of 1.2, meaning that its stock price is 20% more volatile than the S&P 500. Does the media prefer KNSA or ROIV? In the previous week, Roivant Sciences had 1 more articles in the media than Kiniksa Pharmaceuticals International. MarketBeat recorded 13 mentions for Roivant Sciences and 12 mentions for Kiniksa Pharmaceuticals International. Roivant Sciences' average media sentiment score of 0.59 beat Kiniksa Pharmaceuticals International's score of 0.48 indicating that Roivant Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kiniksa Pharmaceuticals International 4 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Roivant Sciences 5 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryKiniksa Pharmaceuticals International and Roivant Sciences tied by winning 8 of the 16 factors compared between the two stocks. Get Kiniksa Pharmaceuticals International News Delivered to You Automatically Sign up to receive the latest news and ratings for KNSA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding KNSA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KNSA vs. The Competition Export to ExcelMetricKiniksa Pharmaceuticals InternationalMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.82B$3.38B$6.11B$10.63BDividend YieldN/A2.29%5.67%4.71%P/E Ratio947.4922.2585.9726.57Price / Sales6.63461.00612.03132.55Price / CashN/A47.2238.5062.09Price / Book5.7410.2112.756.53Net Income-$43.19M-$52.40M$3.31B$276.43M7 Day Performance-1.56%0.86%0.80%-0.88%1 Month Performance2.38%10.39%6.21%3.55%1 Year Performance42.66%27.24%80.34%37.91% Kiniksa Pharmaceuticals International Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KNSAKiniksa Pharmaceuticals International3.6328 of 5 stars$37.89-0.6%$44.29+16.9%+48.6%$2.82B$423.24M947.49220News CoverageAnalyst ForecastROIVRoivant Sciences3.4156 of 5 stars$15.10-0.5%$19.94+32.0%+35.1%$10.36B$23.23M-21.57860Analyst ForecastInsider TradeQGENQIAGEN4.2961 of 5 stars$43.880.0%$49.69+13.2%+11.5%$9.76B$1.98B25.935,765News CoverageAnalyst ForecastELANElanco Animal Health2.5597 of 5 stars$19.63+0.1%$18.33-6.6%+36.2%$9.74B$4.44B22.829,000Analyst UpgradeBBIOBridgeBio Pharma3.9806 of 5 stars$51.96+3.8%$63.94+23.1%+122.3%$9.57B$221.90M-12.70400Analyst ForecastInsider TradeMRNAModerna4.2401 of 5 stars$25.33+3.4%$41.81+65.1%-52.8%$9.53B$3.24B-3.365,800Analyst ForecastVRNAVerona Pharma PLC American Depositary Share1.8164 of 5 stars$106.61-0.1%$109.00+2.2%N/A$9.20B$42.28M-107.6930Positive NewsAnalyst ForecastRVMDRevolution Medicines4.0889 of 5 stars$46.07+4.9%$74.64+62.0%-2.5%$8.21B$11.58M-10.24250Analyst ForecastGRFSGrifols3.8608 of 5 stars$9.93+1.1%$10.30+3.7%+8.0%$6.75B$7.81B8.4923,822News CoveragePositive NewsAnalyst ForecastRYTMRhythm Pharmaceuticals3.3372 of 5 stars$100.64+1.5%$106.64+6.0%+110.2%$6.59B$130.13M-33.44140Analyst ForecastRNAAvidity Biosciences2.1116 of 5 stars$42.63-0.7%$68.32+60.3%+12.6%$6.27B$10.90M-11.97190Analyst ForecastInsider Trade Related Companies and Tools Related Companies Roivant Sciences Alternatives QIAGEN Alternatives Elanco Animal Health Alternatives BridgeBio Pharma Alternatives Moderna Alternatives Verona Pharma PLC American Depositary Share Alternatives Revolution Medicines Alternatives Grifols Alternatives Rhythm Pharmaceuticals Alternatives Avidity Biosciences Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KNSA) was last updated on 10/11/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredForget AI, This Will Be the Next Big Tech BreakthroughAfter picking Nvidia in 2016, before it jumped 27,000%... Jeff Brown is back with what he believes will be ...Brownstone Research | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kiniksa Pharmaceuticals International, plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Kiniksa Pharmaceuticals International With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
